Sangamo Therapeutics completed the court-approved sale of its Lilly Assets to Eli Lilly for $50 million in cash, while Lilly assumed specified related liabilities. For SGMOQ investors, the company warns that common-stock trading during Chapter 11 is highly speculative and prices may bear little relationship to any recovery.

Key Highlights

  • Eli Lilly was selected as the successful bidder during Sangamo Therapeutics’ court-supervised auction process.
  • The transaction covers Sangamo’s AAV capsid engineering, zinc finger protein and Modular Integrase technology platforms.
  • Sangamo reported $155,117,944 in total assets and $97,132,393 in total liabilities in its monthly operating report.

Sangamo Therapeutics, Inc. (OTC: SGMOQ) completed the court-approved sale of its Lilly Assets to Eli Lilly and Company (NYSE: LLY) for $50 million in cash. Eli Lilly also assumed certain specified liabilities tied to the assets. The transaction followed a court-supervised auction process in Sangamo’s Chapter 11 case, with Lilly selected as the successful bidder. The sale covers technology platforms, intellectual property rights, a prion disease program and rights to certain future milestone and Royalty payments.

Lilly Technology Platforms Transferred

The assets sold include Sangamo’s AAV capsid engineering platform, its STAC-BBB capsid and related next-generation variants. The transaction also includes the company’s zinc finger protein technology platform and Modular Integrase genome editing platform. Eli Lilly also acquired Sangamo’s rights to receive certain payments under outlicensing agreements, including future milestone and royalty payments. The $50 million cash consideration was paired with Lilly’s assumption of specified liabilities related to the Lilly Assets. Lilly was also named as guarantor for a provision of the Asset Purchase Agreement.

Auction Produced Lilly Selection

A court order authorized the transaction under the Asset Purchase Agreement. The company continues to operate as a debtor-in-possession under applicable Bankruptcy provisions.

July Financial Position

Total receipts for the current month were $18,058,990, while current-month disbursements reached $15,534,279. Total assets stood at $155,117,944, including $20,386,655 in current assets. Postpetition payables were $18,768,593, and postpetition taxes payable were $269,455. Total liabilities were $97,132,393, leaving ending Equity or net worth of $57,985,551. Sangamo reported current-month gross income of $720,000 and a current-month loss of $11,165,298. Sangamo’s common stock trades on the OTCID Basic Market under SGMOQ, and trading prices may bear little or no relationship to any recovery by holders in the Chapter 11 case.